



University of Groningen

Mathematical predictions of oxygen availability in micro- and macro-encapsulated human and porcine pancreatic islets

Cao, Rui; Avgoustiniatos, Efstathios; Papas, Klearchos; de Vos, Paul; Lakey, Jonathan R T

Published in: Journal of Biomedical Materials Research. Part B: Applied Biomaterials

DOI: 10.1002/jbm.b.34393

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version Publisher's PDF, also known as Version of record

Publication date: 2020

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA): Cao, R., Avgoustiniatos, E., Papas, K., de Vos, P., & Lakey, J. R. T. (2020). Mathematical predictions of oxygen availability in micro- and macro-encapsulated human and porcine pancreatic islets. *Journal of Biomedical Materials Research. Part B: Applied Biomaterials, 108*(2), 343-352. https://doi.org/10.1002/jbm.b.34393

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.



Mathematical predictions of oxygen availability in micro- and macro-encapsulated human and porcine pancreatic islets

Rui Cao¹ | Efstathios Avgoustiniatos² | Klearchos Papas³ | Paul de Vos⁴ |

Jonathan R. T. Lakey^{1,5}

¹Department of Surgery, University of California, Irvine, Orange, California

²Department of Surgery, University of Minnesota, Minneapolis, Minnesota

³Department of Surgery, University of Arizona, Tucson, Arizona

⁴Departments of Pathology and Laboratory Medicine, Division of Immuno-Endocrinology, University of Groningen, Groningen, The Netherlands

⁵Department of Biomedical Engineering, University of California, Irvine, California

Correspondence

Jonathan R. T. Lakey, Department of Surgery, and Biomedical Engineering, University of California, Irvine, 333 City Blvd West Suite 1600, Orange, CA, 92868. Email: jlakey@uci.edu

Funding information Juvenile Diabetes Research Foundation United States of America, Grant/Award Number: 17-2013-288

Abstract

Optimal function of immunoisolated islets requires adequate supply of oxygen to metabolically active insulin producing beta-cells. Using mathematical modeling, we investigated the influence of the pO2 on islet insulin secretory capacity and evaluated conditions that could lead to the development of tissue anoxia, modeled for a 300 µm islet in a 500 μ m microcapsule or a 500 μ m planar, slab-shaped macrocapsule. The pO₂ was used to assess the part of islets that contributed to insulin secretion. Assuming a 500 µm macrocapsule with a 300 µm islet, with oxygen consumption rate (OCR) of 100-300 nmol min⁻¹ mg⁻¹ DNA, islets did not develop any necrotic core. The nonfunctional zone (with no insulin secretion if pO2 < 0.1 mmHg) was 0.3% for human islets (OCR ~100 nmol/min/mg DNA) and 35% for porcine islets (OCR ~300 nmol/min/mg DNA). The OCR of the islet preparation is profoundly affected by islet size, with optimal size of <250 μ m in diameter (human) or <150 μ m (porcine). Our data suggest that microcapsules afford superior oxygen delivery to encapsulated islets than macrocapsules, and optimal islet function can be achieved by encapsulating multiple, small (<150 μ m) islets with OCR of ~100 nmol min⁻¹ mg⁻¹ DNA (human islets) or ~200 nmol min⁻¹ mg⁻¹ DNA (porcine islets).

KEYWORDS

computer modeling, encapsulation, islet, oxygen consumption rate, oxygen diffusion

1 | INTRODUCTION

Immunoisolation of pancreatic islets within bioencapsulation devices has been proposed to be an effective strategy to circumvent chronic immunosuppression in islet transplantation. Important advances have been made in the last two decades in the fields of biomaterial device design, needs for islets in the capsules and the immune responses provoked by immunoisolated pancreatic islets (Scharp & Marchetti, 2014). Human trials are underway; temporary but reproducible islet function and survival has been reported with encapsulated pancreatic islet grafts transplanted into human diabetic patients (Jacobs-Tulleneers-Thevissen et al., 2013). Also, it has been shown that encapsulation may contribute to solving shortage of donor tissue as prolonged survival of xenotransplanted islet grafts has been demonstrated in both chemically induced and autoimmune diabetic rodents (Fritschy et al., 1994), dogs (Calafiore et al., 2004), and nonhuman primates (Dufrane, Goebbels, Saliez, Guiot, & Gianello, 2006). There is consensus that porcine islets may serve as an inexhaustible source of islets for human diabetics (Ekser et al., 2012). Despite these successes and potentials of the approach, a persistent and fundamental barrier has to be overcome since graft survival varies

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2019 The Authors. Journal of Biomedical Materials Research Part B: Applied Biomaterials published by Wiley Periodicals, Inc.

Paul de Vos and Jonathan R. T. Lakey should be considered co-senior authors

considerably from several days to months (de Vos, Andersson, Tam, Faas, & Halle, 2006; de Vos, Faas, Strand, & Calafiore, 2006).

While encapsulation within immunoprotective membranes can be performed in several ways (macroencapsulation, microencapsulation, or conformal coating), we will limit further discussion to macro- and microcapsules, where it has been theorized that graft oxygenation would be significantly impaired. In macroencapsulation, beta cells derived from donor islets or stem cells are enveloped in relatively large diffusion chambers with barriers that selectively exclude immune responses. In microencapsulation the islets are packaged within micronsized capsules ranging around 600um (Riccardo, 2018). In both configurations, islets are unable to connect to host micro-vasculature as the encapsulation barrier prevents host endothelium from connecting with the islet. As a result, vital nutrients for cell survival are at a distance and their continued consumption by islet grafts results in diffusion gradients; the nutrients will be available in lower concentrations than available in the ambient interstitium. This phenomenon is more consequential in the case of oxygen (O₂) than other nutrients because (a) the availability of oxygen to islets depends on O_2 partial pressure (p O_2) rather than on O_2 saturation in the adjacent microvasculature. (b) O_2 is poorly soluble in aqueous media, and (c) islets are metabolically highly active and consume large quantities of O₂ relative to their tissue volume. Hypoxia is therefore considered to be a major contributor to the limitations in duration of survival of encapsulated islet grafts (Bloch et al., 2006).

Although researchers have long stressed on the indispensability of adequate tissue oxygenation to ensure favorable transplant outcomes in encapsulated islet transplantation (Avgoustiniatos & Colton, 2006; Colton & Avgoustiniatos, 1991; Papas et al., 2007; Souza et al., 2011), few studies address the severity of this issue and expound on the various factors that may influence oxygen bioavailability in encapsulated islets. To gain more insight into the severity of this problem, we investigated the influence of a number of critical factors on encapsulated islet oxygenation by using mathematical modeling algorithms.

- The partial pressure of oxygen (pO₂) at the transplantation site (peritoneal cavity), which is around 40 mmHg (about 5.5% of saturation pressure) (Nöth et al., 1999).
- 2. The oxygen consumption rate (OCR) of the islets which is different in human islets and porcine islets and also dependent on the quality of the islet preparation (Papas et al., 2007).
- Device geometry; microcapsules have a more optimal surface to volume ratio which predictably leads to a higher pO₂ than in macrocapsules.
- 4. The islet load and the spatial distribution of the islets in the device.
- 5. The influence of islet size.

2 | MATERIALS AND METHODS

The model we have developed predicts the pO_2 in the islets of different sizes and in different capsule geometries. For microcapsules, spherical geometry can minimize shear stress and friction with surrounding tissues. Also, the surface area to volume ratio of microcapsules is large enough for nutrition transportation between surrounding blood vessels



FIGURE 1 Finite-element mesh and boundary conditions for a single 300 μ m islet in a 500 μ m alginate microcapsule. Oxygen availability at the surface (P_s) is assumed to be close to the parameter of the equilibrium pO₂

and microcapsules. For macrocapsules, planar structure could provide large contact area with blood vessels to get enough oxygen supply. The calculations below were performed for alginate-PLL capsules (Figures 1 and 2) and alginate-based planar macrocapsules. Since hypoxic islets do not secrete insulin in response to stimulation with glucose (Dionne, Colton, & Yarmush, 1989, 1993), the pO_2 will be used to indirectly measure the fraction of islets that contribute to insulin secretion.

2.1 | Modeling assumptions

2.1.1 | Islet size

Simulations were run for uniformly sized and spatially distributed islets. Two different islet diameters were used: 100 and 300 μ m.

2.1.2 | Geometries

For most calculations microcapsule and macrocapsule diameter or thickness was varied to calculate the effect of the size of the device on oxygen bioavailability to the islets encapsulated within.



FIGURE 2 Finite-element mesh and boundary conditions for four 100 μ m islets in a 500 μ m alginate microcapsule. Oxygen availability at the surface (P_s) is assumed to be close to the parameter of the equilibrium pO₂

| Change (%) | Case | Case | Case | 50.34 | 34.18 | 3.23 | 50.34 | 34.18 | 3.23 | 50.34 | 34.18 | 3.23 | |
|---|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---|
| Ins. Func. (%) | 49.66 | 65.82 | 96.77 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |
| Change (%) | Base | Base | Base | 20.40 | 8.26 | 0.00 | 20.40 | 8.26 | 0.00 | 20.40 | 8.26 | 0.00 | |
| Oxyg. Vol. Frac. (%) | 79.60 | 91.74 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | • |
| Total volume (× 10 ⁶ μm ³) | 14.1370 | 14.1370 | 14.1370 | 0.5236 | 0.5236 | 0.5236 | 0.5236 | 0.5236 | 0.5236 | 1.0472 | 1.0472 | 1.0472 | |
| Functioning volume (× 10 ⁶ μm ³) | 7.0210 | 9.3047 | 13.6810 | 0.5236 | 0.5236 | 0.5236 | 0.5236 | 0.5236 | 0.5236 | 1.0472 | 1.0472 | 1.0472 | : |
| Anoxic volume (× 10 ⁶ μm ³) | 2.8837 | 1.1674 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| OCR Nmol /min/mg DNA | 300 | 200 | 100 | 300 | 200 | 100 | 300 | 200 | 100 | 300 | 200 | 100 | |
| lslet diameter (µm) | 300 | 300 | 300 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| Islets | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 4 | 4 | 4 | |
| Gel rim thickness (µm) | 100 | 100 | 100 | 200 | 200 | 200 | 100 | 100 | 100 | 20 | 20 | 20 | |
| Device thickness (µm) | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | |
| Alginate Conc. (wt/vol%) | e | e | e | e | e | e | e | e | e | e | e | e | |
| Device surface pO ₂ (mm hg) | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | |
| Geometry | Capsule | |

TABLE 1 Mathematical modeling of oxygen diffusion into a 500 µm-thick capsule using finite element analysis

Note: It is assumed that the pO₂ drops by 10 mmHg at the surface of the device. Utilizing smaller islets is predicted to significantly increase the oxygenated fraction and eliminates islet anoxia. It is predicted that neither increasing the number of islets encapsulated within from one to four nor reducing the gel rim thickness would significantly affect islet oxygenation or insulin release. Low OCR preparations (human islets and high quality porcine islets) are predicted to have superior islet function when compared with high OCR preparations. Note: It is assumed that the pO_2 drops by 10 mmHg at the Abbreviation: OCR, oxygen consumption rate.

•

| s |
|--|
| ays |
| nt ar |
| mer |
| e e |
| inite |
| ng f |
| o usi |
| slab |
| ліс қ |
| Ŧ |
| Ξ |
| mi 00 |
| a 500 µm |
| into a 500 μm |
| ion into a 500 μm |
| ffusion into a 500 μm |
| n diffusion into a 500 μm |
| cygen diffusion into a 500 μm |
| of oxygen diffusion into a 500 μm |
| ng of oxygen diffusion into a 500 μm |
| deling of oxygen diffusion into a 500 μm |
| l modeling of oxygen diffusion into a 500 μm |
| Itical modeling of oxygen diffusion into a 500 μm |
| ematical modeling of oxygen diffusion into a 500 μm |
| 1athematical modeling of oxygen diffusion into a 500 μm |

TABLE 2

| Geometry | Device surface pO ₂ | vol/vol islet / alginate layer (%) | Alginate Conc. (wt/vol%) | # of islet mono layers | Single islet layer thickness (µm) | lslet diameter (μm) | Cyl rim thickness (µm) | OCR Nmol / min/mg DNA | Anoxic volume (× 10 ⁶ μm ³) | Functioning volume (× 10 ⁶ μm ³) | Total volume (× 10 ⁶ μm ³) | Oxyg. Vol. Frac. (%) | Change (%) | Ins. Func. (%) | Change (%) |
|--|---|--|--|--|--|--|---|--------------------------------------|--|---|---|---|--|---|-----------------------------|
| Slab | 40 | 25 | ю | 1 | 300 | 300 | 93.95 | 300 | 4.9517 | 3.5511 | 14.1370 | 64.97 | Base | 25.12 | Case |
| Slab | 40 | 25 | e | 1 | 300 | 300 | 93.95 | 200 | 2.7747 | 5.7711 | 14.1370 | 80.37 | Base | 40.82 | Case |
| Slab | 40 | 25 | e | 1 | 300 | 300 | 93.95 | 100 | 0.0408 | 11.1950 | 14.1370 | 99.71 | Base | 79.19 | Case |
| Slab | 40 | 25 | 1 | 1 | 300 | 300 | 93.95 | 300 | 4.8557 | 3.6951 | 14.1370 | 65.65 | 0.68 | 26.14 | 1.02 |
| Slab | 40 | 25 | 1 | 1 | 300 | 300 | 93.95 | 200 | 2.6866 | 5.9459 | 14.1370 | 81.00 | 0.62 | 42.06 | 1.24 |
| Slab | 40 | 25 | 1 | 1 | 300 | 300 | 93.95 | 100 | 0.0282 | 11.3490 | 14.1370 | 99.80 | 0.09 | 80.28 | 1.09 |
| Slab | 40 | 20 | e | 1 | 300 | 300 | 122.86 | 300 | 4.5323 | 4.2168 | 14.1370 | 67.94 | 2.97 | 29.83 | 4.71 |
| Slab | 40 | 20 | e | 1 | 300 | 300 | 122.86 | 200 | 2.4009 | 6.5427 | 14.1370 | 83.02 | 2.64 | 46.28 | 5.46 |
| Slab | 40 | 20 | e | 1 | 300 | 300 | 122.86 | 100 | 0.0027 | 11.8480 | 14.1370 | 99.98 | 0.27 | 83.81 | 4.62 |
| Slab | 40 | 25 | e | 2 | 150 | 100 | 15.67 | 300 | 0.0153 | 0.1752 | 0.5236 | 97.08 | 32.11 | 33.46 | 8.35 |
| Slab | 40 | 25 | e | 2 | 150 | 100 | 15.67 | 200 | 0 | 0.3701 | 0.5236 | 100.00 | 19.63 | 70.67 | 29.85 |
| Slab | 40 | 25 | e | 2 | 150 | 100 | 15.67 | 100 | 0 | 0.5236 | 0.5236 | 100.00 | 0.29 | 100.00 | 20.81 |
| Slab | 40 | 20 | e | 2 | 150 | 100 | 23.54 | 300 | 0 | 0.2442 | 0.5236 | 100.00 | 35.03 | 46.64 | 21.52 |
| Slab | 40 | 20 | e | 2 | 150 | 100 | 23.54 | 200 | 0 | 0.5183 | 0.5236 | 100.00 | 19.63 | 98.98 | 58.16 |
| Slab | 40 | 20 | С | 2 | 150 | 100 | 23.54 | 100 | 0 | 0.5236 | 0.5236 | 100.00 | 0.29 | 100.00 | 20.81 |
| <i>Note:</i> Assun islet/alginat release and | nptions incl e layer and eliminate is | ude a gel rim thi the thickness of let anoxia. Low (| ickness of 1(^f the islet lay OCR prepara | 00 μm, a c€ 'er, utilizinξ ations (hun | entral gel thickne: g smaller islets ar nan islets and hig | ss of 300 μm ar nd increasing th th quality porcir | id that the pO ₂ di e number of islet ie islets) are predi | rops by 1(monolay€ icted to h | 0 mmHg at the ers. All of them ave superior is | e surface of th are predicted slet function v | ie device. Vari d to significani when compare | ables inclu tly increase d with hig | ide reducing t e the oxygen. h OCR prepa | the percent ated fractio rations. | age of the r and insulin |

Abbreviation: OCR, oxygen consumption rate.



300 µm

Islet-Alginate layer

300 um

Islet-Alginate layer

50 μm Alginate layer \$
400 μm Alginate layer \$
50 μm Alginate layer \$



Other assumptions have to be made regarding geometry of the encapsulating device, thickness of islet layer, islet viability as measured by oxygen consumption ratio, concentration of alginate, surface coating, external pO_2 , presence of anoxic core, and insulin secretion. These modeling assumption are provided in Supplement S1.

2.2 | Theoretical mathematical models and equations

The equations used for mathematical modeling is described in Supplement S2. These equations describe zero-order kinetics of the pressure diffusion and the impact of volume on oxygen partial pressure.

3 | RESULTS

3.1 | Oxygenation in transplanted islets

In addition to the internal ΔpO_2 , the consumption of O_2 inside the islet causes an external ΔpO_2 through the immunoisolation barrier and presence of any host tissue between the islet and the nearest O_2 source (usually blood vessels). The external ΔpO_2 can increase by competition of neighboring transplanted islets for O_2 .

Total ΔpO_2 = Internal ΔpO_2 + External ΔpO_2 .

Thus, it is evident that the total ΔpO_2 can be much greater than equilibrium tissue pO_2 (e.g., 40 mmHg).

When that happens, anoxic cores develop inside the islets. Oxygenation shows fraction of non-anoxic and non-hypoxic area. Even if total ΔpO_2 less than equilibrium pO_2 and so anoxic cores are absent, the islets can be exposed to low pO_2 parameters that can negatively impact insulin secretion. At such low pO_2 parameters, insulin secretion can be affected even if no anoxic core exists. Depending on the mode of transplantation, pO_2 effects on long-term insulin secretion have to be taken into consideration.

3.2 | Effect of geometry of the device

The oxygen profiles were modeled for a 300 μ m islet in a 500 μ m microcapsule or in a 500 μ m planar, slab shaped macrocapsule. This was done for islets with an OCR of 100 nmol min⁻¹ mg⁻¹ DNA and an OCR of 300 nmol min⁻¹ mg⁻¹ DNA. The calculations were performed with a pO₂ of 40 mmHg. The zone that does not contribute anymore to insulin secretion, that is, the zone where pO₂ drops below

0.1 mmHg, was 3.2% for islets with an OCR of 100 nmol min⁻¹ mg⁻¹ DNA and 50.3% for islets with a pO₂ of 300 nmol min⁻¹ mg⁻¹ DNA.

Î

t

3.2.1 | Five hundred micrometer diameter microcapsule

A single 300 μ m diameter islet in the center of a 500 μ m diameter alginate capsule has 80% of its volume oxygenated even at the highest OCR/DNA examined in this study. Insulin secretion varied between 50 and 97%, depending on the OCR/DNA (Table 1). In sharp contrast, even 4× (the highest number that allows the use of axisymmetrical modeling) 100 μ m diameter islets in one capsule exhibit 100% oxygenation and insulin secretory capacity, as shown in Figure 2.

3.2.2 | Five hundred micrometer thick slab (macrocapsule)

At 25% vol/vol, 300 μ m diameter islets are predicted to be oxygenated for 65–100%, depending on the islet preparation OCR/DNA. Insulin secretion is predicted to be 25–79%, again depending on the OCR/DNA (Table 2). Reduction of the alginate concentration from 3 to 1% conveys a small improvement in the order of 1% (of the nonoxygen limited parameter) in both oxygenation and insulin secretion. Reduction of the islet content in the composite layer to 20% improves oxygenation by less than 3% and also improves fractional insulin secretion, that is, the fraction of islet tissue that is able to release insulin in response to a glucose challenge, by about 5%. Fractional insulin secretion is a measure of the efficiency at which the transplanted tissue can be utilized. Bilayers (explained above) of 100 μ m diameter islets perform much better and experience virtually no anoxia and smaller loss of insulin secretory capacity.

3.2.3 | One thousand, one hundred micrometer thick slab (macrocapsule)

This design exhibits increased oxygenation by as much as 15% of the total islet volume and smaller loss of insulin secretory capacity by about 25%. This result may be counter-intuitive as in this geometry each islet layer is oxygenated mainly from one side of the slab rather than both (Figure 3, Table 3). Further analysis is required, but it is quite possible that the improvement is due to the shorter thickness of alginate between the islet and the oxygen source in this geometry (50 μ m) relative to the 500 μ m thick slab (100 μ m).

| | Device surface | vol/vol islet / | Alginate | # of islet | Single islet laver | Islet | Cvl rim | OCR | Anoxic | Functioning | Total | Охув. | | | |
|-------------|----------------------------|-----------------------|--------------------|----------------|-----------------------|------------------|-------------------|---------------------|--|--|--|-------------------|--------------|-------------------|----------------|
| Geometry | pO ₂ (mm hg) | alginate layer (%) | Conc. (wt/vol%) | mono layers | thickness (µm) | diameter (μm) | thickness (μm) | nmol/min /mg DNA | volume (x 10 ⁶ μm ³) | volume (× 10 ⁶ μm ³) | volume (x 10 ⁶ μm ³) | Vol. Frac. (%) | Change (%) | Ins. Func. (%) | Change (%) |
| Slab | 40 | 25 | т | 2 | 300 | 300 | 93.9489743 | 300 | 7.1063 | 2.1051 | 14.137 | 49.73 | Base | 14.89 | Case |
| Slab | 40 | 25 | e | 2 | 300 | 300 | 93.9489743 | 200 | 5.1416 | 3.1444 | 14.137 | 63.63 | Base | 22.24 | Case |
| Slab | 40 | 25 | S | 2 | 300 | 300 | 93.9489743 | 100 | 1.4247 | 6.2246 | 14.137 | 89.92 | Base | 44.03 | Case |
| Slab | 40 | 20 | e | 2 | 300 | 300 | 122.8612788 | 300 | 6.4903 | 2.3918 | 14.137 | 54.09 | 4.36 | 16.92 | 2.03 |
| Slab | 40 | 20 | e | 2 | 300 | 300 | 122.8612788 | 200 | 4.4385 | 3.6330 | 14.137 | 68.60 | 4.97 | 25.70 | 3.46 |
| Slab | 40 | 20 | ю | 2 | 300 | 300 | 122.8612788 | 100 | 0.8360 | 7.4844 | 14.137 | 94.09 | 4.16 | 52.94 | 8.91 |
| ote: Assump | otions inclu | ide a gel rim | thickness o | f 50 µm, a c | entral gel thic | ckness of 4 | 100 µm and that | the pO_2 drops by | 10 mmHg at t | the surface of t | the device. Red | lucing the p | ercentage of | the islet/alg | inate layer is |

predicted to significantly increase the oxygenated fraction and insulin release and eliminate islet anoxia. Low OCR preparations (human islets and high quality porcine islets) are predicted to have superior islet function when compared with high OCR preparations.

Abbreviation: OCR, oxygen consumption rate.

The oxygen availability within macrocapsules (Tables 2 and 3) were different from that of microcapsules (Table 1). For a 500 µm microcapsule, at an OCR of 100 nmol min⁻¹ mg⁻¹ DNA (human islet preparations), 0% of the islet was anoxic. At an OCR of 300 nmol min⁻¹ mg⁻¹ DNA (porcine islet preparations) this increased to 20% of the islet volume. The zone that dropped below pO2 0.1 mmHg, was 3% (OCR of 100 nmol min⁻¹ mg⁻¹ DNA) and 50% (OCR of 300 nmol min⁻¹ mg⁻¹ DNA) of the islet volume. For a 500 μ m capsules, 0.3% of the islet was anoxic (OCR of 100 nmol/min/mg DNA) this increased to 35% (OCR of 300 nmol min⁻¹ mg⁻¹ DNA). The zone that dropped below pO2 0.1 mmHg was 21% (OCR of 100 nmol min⁻¹ mg⁻¹ DNA) and 75% (OCR of 300 nmol min⁻¹ mg⁻¹ DNA) of the islet volume (Figure 4).

3.3 | Effect of islet size, spatial distribution and load in microcapsules

Next the oxygen profiles were calculated for microencapsulated islets of 100 µm diameter either as a single islet or as a group of four islets per capsule, comparing with a microcapsule containing a 300 µm islet. With four islets of 100 um, the islet developed no anoxic core (Figure 5), in comparison to 300 µm islet (Figure 6). The zone that does not contribute anymore to insulin secretion, was 51.34% for 300 μ m islets (Figure 6) while it was 0% for a single 100 μ m islets and for a cluster of four 100 μm islets (Figure 5). Notably, four 100 μm islets have only 4/27 of the volume of one 300 μ m islet.

3.4 | Effect of pO₂ at the transplant site

The oxygen tension at the transplant site will drop when encapsulated islets with a high OCR are implanted (Papas et al., 2005). Therefore, the effect of lowering pO2 was investigated on microcapsules containing four islets each (Figure 5). Lowering the pO_2 to a parameter to 20 mmHg did not lead to the development of anoxic zone in microencapsulated islets (Figure 5). The zone that does not contribute anymore to insulin secretion was 17%.

3.5 | Effect of the oxygen consumption rate of the islets

As the oxygen consumption rate of islets varies between species and even between isolations, we calculated the maximum islet-diameter without anoxic cores for islet preparations with an OCR varying between 50 and 900 nmol min⁻¹ mg⁻¹ DNA. Note that the higher parameters are just applied for modeling purposes as the maximum OCR ever observed was 460 nmol min⁻¹ mg⁻¹ DNA (Personal communication Papas KK). The parameters were calculated for a singleislet in a 500 μm capsule and for a pO_2 parameter of 20, 30, and 40 mmHg. As shown in Figure 7, the OCR of the islet preparation has the most profound effect on the maximum islet-size that can be used. Islets larger that 150 µm should be avoided at OCR-parameters of 200-300 nmol min⁻¹ mg⁻¹ DNA, that is, typical OCR ranges for porcine islet isolations. When applying human islets with a typical

FIGURE 4 pO_2 surface plot for 300 µm diameter islets encapsulated within a 500 µm-thick alginate capsule, comparing islet with OCR of 100 nmol/min/mg DNA versus 300 nmol min⁻¹ mg⁻¹ DNA. pO_2 varies from 40 mmHg (red) to 0.1 mmHg (white). Oxygen availability at the surface (P_s) is assumed to be close to the parameter of the equilibrium pO_2 (40 mmHg intraperitoneally)



parameter of 100–150 nmol min⁻¹ mg⁻¹ DNA (Papas et al., 2007) diameters up to 250 μ m can be applied. The pO₂ parameter in the immediate vicinity of the capsules has a less pronounced effect on the maximum islet diameter to be applied, but still with every drop of 10 mmHg a decrease of 50 μ m in maximum islet diameter was observed (Figure 7).

4 | DISCUSSION

Sufficient supply of oxygen to islets is not only important for function and survival of cells in the capsules, but also for host responses.



FIGURE 5 pO_2 surface plot for 4 × 100 µm diameter islets in a single 500 µm diameter alginate capsule. pO_2 varies from 40 mmHg (red) to 0.1 mmHg (white). Oxygen availability at the surface (P_s) is assumed to be close to the parameter of the equilibrium pO_2 (40 mmHg intraperitoneally) Hypoxia causes encapsulated islets to become necrotic and to produce danger-associated molecular patterns (DAMPS) (Paredes-Juárez, Spasojevic, Faas, & de Vos, 2014). DAMPS are highly immunogenic and can provoke severe host responses. Also, islets under hypoxic conditions produce nitric oxide (NO) that can induce cell-death in the islets (Paredes-Juarez et al., 2015). Hypoxia also induces upregulation of chemotactic cytokines such as monocyte chemoattractant protein 1 (MCP-1), which attract proinflammatory cells such as macrophages and neutrophils. These cells will induce profound damage to the graft in the immediate period after transplantation (Fraker, Alejandro, & Ricordi, 2002). Thus, hypoxia not only induces direct deleterious effects on the islets in the capsules, but it will also result in a brisk immune response against the encapsulated grafts.

An improved understanding of the interplay of oxygen diffusion and consumption rate in devices is critical to improve oxygen supply to islets. Current efforts to solve the oxygen supply hurdle include engineering of islets to render them more resistant to hypoxic conditions and supply of components to enhance oxygen tensions in capsules. These include administration of organic molecules with high oxygen retention capabilities such as perfluorocarbons, silicone oils, or soybean oils (Cowley et al., 2012; Fraker et al., 2002; Papas et al., 2005). Another approach is the supply of oxygen by an external oxygen tank (Barkai et al., 2013).

The results of this study highlight the multitude of device and tissue parameters that influence oxygen bioavailability within islet encapsulation devices. Several published studies have demonstrated that smaller islets are more likely to have a favorable outcome after intraportal or renal subcapsular transplantation (Lehmann et al., 2007; Macgregor et al., 2006). Two-dimensional axi-symmetric modeling predicts that encapsulated islet preparations that contain smaller islets (~100 μ m) are less likely to demonstrate anoxia or suffer a reduction in insulin release when compared with large islets (~300 μ m) after



FIGURE 6 pO_2 surface plot for 300 μ m diameter islets encapsulated within a 500 μ m-thick alginate capsule. pO_2 varies from 40 mmHg (red) to 0.1 mmHg (white). Oxygen availability at the surface (P_s) is assumed to be close to the parameter of the equilibrium pO_2 (40 mmHg intraperitoneally)

intraperitoneal transplantation, suggesting favorable outcomes with smaller islets.

The results of this study also suggest that islet with lower OCRs are comparatively less likely to experience anoxia and a decline in insulin release after encapsulation and intraperitoneal transplantation. While no studies have evaluated islet OCR in encapsulated islets post-transplantation, with unencapsulated islets transplanted into portal veins or renal subscapular spaces, islet OCR has been demonstrated to be a reliable predictor of a successful outcome; the higher the OCR, the greater the chances of hyperglycemia reversal in diabetic recipients (Papas et al., 2015; Pepper et al., 2012).

Our model also predicts that human islet preparations (OCR ~100 nmol/min/mg DNA) should theoretically fare better than porcine islet preparations (OCR 200-300 nmol/min/mg DNA). While no comparative studies have been performed to specifically evaluate this hypothesis in vivo, Hals IK et al., noted that encapsulated human islets did not demonstrate evidence of hypoxia-induced graft injury post transplantation (Hals, Rokstad, Strand, Oberholzer, & Grill, 2013); unfortunately, no similar studies have been performed with encapsulated porcine islets to date.

Modeling results also predict that oxygen bioavailability is greater within microcapsules than macrocapsules, albeit there are limitations



FIGURE 7 Effect of islet preparation OCR on encapsulated islet oxygenation. The graph predicts the "maximum allowable islet diameter without an anoxic core" for human and porcine islet preparations encapsulated within a 500 μ m diameter capsule assuming a ratio of one 300 μ m diameter islet per capsule. If the pO₂ at the capsule surface is lowered, the "maximum allowable islet diameter without an anoxic core" reduces correspondingly. OCR, oxygen consumption rate

to the scope of this conclusion as only two symmetric alginate-based planar macrocapsule constructs were evaluated. Cornolti R et al., reported that after 48 hours of in vitro culture, both micro and macroencapsulated bovine islets demonstrated no significant changes in OCR; however, only one hollow-fiber macrocapsule construct was evaluated in this study and no in vivo experiments were performed which makes it difficult to interpret the results reported (Cornolti et al., 2009). Our results might also explain why researchers have reported successful return to euglycemia only when either oxygen supplementation (Ludwig et al., 2012; Pedraza, Coronel, Fraker, Ricordi, & Stabler, 2012) or prevascularization (Kriz et al., 2012; Pepper et al., 2015) was employed with macrocapsule devices transplanted into diabetic recipients. However, results obtained with microcapsules have been far more encouraging (Hals et al., 2013; Pareta et al., 2014; Yang et al., 2016).

4.1 | Model validation

In vivo study has shown presence of oxygen gradient in the capsule. However, in vitro validation would be necessary to measure oxygen gradient within islets. Also, since an oxygen sink can significantly change pO_2 at the surface of each device, pO_2 need to be tracked for device with oxygen sink. The development of implantable oxygen sensors would enable determination of tissue pO_2 at various implant sites, thus greatly increasing the predictive accuracy of our model (Weidling, Sameni, Lakey, & Botvinick, 2014).

5 | CONCLUSIONS

Encapsulated islet oxygenation is a serious issue. Modeling is a powerful tool to evaluate designs before experiments are carried out. Modeling is

8

limited by the accuracy of the assumptions and parameters used, but it is reliable as long as measurements for parameters that are preparationspecific (e.g., OCR) or are not well characterized (e.g., equilibrium pO_2 at transplantation site before and after transplantation) taken into account to make specific predictions and accurately evaluate biomaterial device design to improve transplantation outcomes.

ACKNOWLEDGMENTS

This study was funded by Juvenile Diabetes Research Foundation grant # 17-2013-288, and the Department of Surgery at University of California Irvine.

CONFLICT OF INTEREST

The authors declare no financial conflict of interest.

AUTHOR CONTRIBUTIONS

RC, JL, and PdV contributed to writing of the manuscript. EA contributed the figures and calculations done in the manuscript. KP contributed the OCR/DNA analysis done in the manuscript. EB and PdV contributed to the engineering analysis done in the manuscript. All authors reviewed the manuscript.

REFERENCES

- Avgoustiniatos, E. S., & Colton, C. K. (2006). Effect of external oxygen mass transfer resistances on viability of immunoisolated tissue. *Annals* of the New York Academy of Sciences, 831, 145–167.
- Barkai, U., Weir, G. C., Colton, C. K., Ludwig, B., Bornstein, S. R., Brendel, M. D., ... Rotem, A. (2013). Enhanced oxygen supply improves islet viability in a new bioartificial pancreas. *Cell Transplantation*, 22, 1463–1476.
- Bloch, K., Papismedov, E., Yavriyants, K., Vorobeychik, M., Beer, S., & Vardi, P. (2006). Photosynthetic oxygen generator for bioartificial pancreas. *Tissue Engineering*, 12, 337–344.
- Calafiore, R., Basta, G., Luca, G., Calvitti, M., Calabrese, G., Racanicchi, L., ... Brunetti, P. (2004). Grafts of microencapsulated pancreatic islet cells for the therapy of diabetes mellitus in non-immunosuppressed animals. *Biotechnology and Applied Biochemistry*, 39, 159–164.
- Colton, C. K., & Avgoustiniatos, E. S. (1991). Bioengineering in development of the hybrid artificial pancreas. *Journal of Biomechanical Engineering*, 113, 152–170.
- Cornolti, R., Figliuzzi, M., & Remuzzi, A. (2009). Effect of micro- and macroencapsulation on oxygen consumption by pancreatic islets. *Cell Transplantation*, *18*, 195–201.
- Cowley, M. J., Weinberg, A., Zammit, N. W., Walters, S. N., Hawthorne, W. J., Loudovaris, T., ... Grey, S. T. (2012). Human islets express a marked proinflammatory molecular signature prior to transplantation. *Cell Transplantation*, 21, 2063–2078.
- de Vos, P., Andersson, A., Tam, S. K., Faas, M. M., & Halle, J. P. (2006). Advances and barriers in mammalian cell encapsulation for treatment of diabetes. *Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry*, *6*, 139–153.
- de Vos, P., Faas, M. M., Strand, B., & Calafiore, R. (2006). Alginate-based microcapsules for immunoisolation of pancreatic islets. *Biomaterials*, 27, 5603–5617.

- Dionne, K. E., Colton, C. K., & Yarmush, M. L. (1989). Effect of oxygen on isolated pancreatic tissue. ASAIO Journal, 35, 739–741.
- Dionne, K. E., Colton, C. K., & Yarmush, M. L. (1993). Effect of hypoxia on insulin secretion by isolated rat and canine islets of Langerhans. *Diabe*tes, 42, 12–21.
- Dufrane, D., Goebbels, R.-M., Saliez, A., Guiot, Y., & Gianello, P. (2006). Six-month survival of microencapsulated pig islets and alginate biocompatibility in primates: Proof of concept. *Transplantation*, 81, 1345-1353.
- Ekser, B., Ezzelarab, M., Hara, H., van der Windt, D. J., Wijkstrom, M., Bottino, R., ... Cooper, D. K. (2012). Clinical xenotransplantation: The next medical revolution? *The Lancet*, *379*, 672–683.
- Fraker, C. A., Alejandro, R., & Ricordi, C. (2002). Use of oxygenated perfluorocarbon toward making every pancreas count. *Transplantation*, 74, 1811–1812.
- Fritschy, W. M., de Vos, P., Groen, H., Klatter, F. A., Pasma, A., Wolters, G. H., & van Schilfgaarde, R. (1994). The capsular overgrowth on microencapsulated pancreatic islet grafts in streptozotocin and autoimmune diabetic rats. *Transplant International*, 7, 264–271.
- Hals, I. K., Rokstad, A. M., Strand, B. L., Oberholzer, J., & Grill, V. (2013). Alginate microencapsulation of human islets does not increase susceptibility to acute hypoxia. *Journal Diabetes Research*, 2013, 1–9.
- Jacobs-Tulleneers-Thevissen, D., Chintinne, M., Ling, Z., Gillard, P., Schoonjans, L., Delvaux, G., ... Pipeleers, D. (2013). Beta cell therapy consortium EU-FP7. Sustained function of alginate-encapsulated human islet cell implants in the peritoneal cavity of mice leading to a pilot study in a type 1 diabetic patient. *Diabetologia*, *56*, 1605–1614.
- Kriz, J., Vilk, G., Mazzuca, D. M., Toleikis, P. M., Foster, P. J., & White, D. J. (2012). A novel technique for the transplantation of pancreatic islets within a vascularized device into the greater omentum to achieve insulin independence. *The American Journal of Surgery*, 203, 793–797.
- Lehmann, R., Zuellig, R. A., Kugelmeier, P., Baenninger, P. B., Moritz, W., Perren, A., ... Spinas, G. A. (2007). Superiority of small islets in human islet transplantation. *Diabetes*, 56, 594–603.
- Ludwig, B., Rotem, A., Schmid, J., Weir, G. C., Colton, C. K., Brendel, M. D., ... Barkai, U. (2012). Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone releasing hormone agonist. *Proceedings of the National Academy of Sciences*, 109, 5022–5027.
- Macgregor, R. R., Williams, S. J., Tong, P. Y., Kover, K., Moore, W. V., & Stehno-Bittel, L. (2006). Small rat islets are superior to large islets in in vitro function and in transplantation outcomes. *American Journal of Physiology. Endocrinology and Metabolism*, 290, E771–E779.
- Nöth, U., Gröhn, P., Jork, A., Zimmermann, U., Haase, A., & Lutz, J. (1999). 19F-MRI in vivo determination of the partial oxygen pressure in Perfluorocarbon-loaded alginate capsules implanted into the peritoneal cavity and different tissues. *Magnetic Resonance in Medicine*, 42, 1039–1047.
- Papas, K. K., Avgoustiniatos, E. S., Tempelman, L. A., Weir, G. C., Colton, C. K., Pisania, A., ... Hering, B. J. (2005). High-density culture of human islets on top of silicone rubber membranes. *Transplantation Proceedings*, 37, 3412–3414.
- Papas, K. K., Bellin, M. D., Sutherland, D. E., Suszynski, T. M., Kitzmann, J. P., Avgoustiniatos, E. S., ... Hering, B. J. (2015). Islet oxygen consumption rate (OCR) dose predicts insulin independence in clinical islet autotransplantation. *PLoS ONE*, 10, e1034428.
- Papas, K. K., Colton, C. K., Nelson, R. A., Rozak, P. R., Avgoustiniatos, E. S., Scott, W. E., 3rd, ... Hering, B. J. (2007). Human islet oxygen consumption rate and DNA measurements predict diabetes reversal in nude mice. *American Journal of Transplantation*, 7, 707–713.
- Paredes-Juarez, G. A., Sahasrabudhe, N. M., Tjoelker, R. S., de Haan, B. J., Engelse, M. A., de Koning, E. J., ... de Vos, P. (2015). DAMP production by human islets under low oxygen and nutrients in the presence or absence of an immunoisolating-capsule and necrostatin-1. *Scientific Reports*, 5, 14623.

- Pareta, R., McQuilling, J. P., Sittadjody, S., Jenkins, R., Bowden, S., Orlando, G., ... Opara, E. C. (2014). Long-term function of islets encapsulated in a redesigned alginate microcapsule construct in Omentum pouches of immune-competent diabetic rats. *Pancreas*, 43, 605–613.
- Pedraza, E., Coronel, M. M., Fraker, C. A., Ricordi, C., & Stabler, C. L. (2012). Preventing hypoxia-induced cell death in beta cells and islets via hydrolytically activated, oxygen-generating biomaterials. *Proceedings of the National Academy of Sciences*, 109, 4245–4250.
- Pepper, A. R., Hasilo, C. P., Melling, C. W., Mazzuca, D. M., Vilk, G., Zou, G., & White, D. J. (2012). The islet size to oxygen consumption ratio reliably predicts reversal of diabetes posttransplant. *Cell Transplantation*, 21, 2797–2804.
- Pepper, A. R., Pawlick, R., Gala-Lopez, B., MacGillivary, A., Mazzuca, D. M., White, D. J., ... Shapiro, A. M. (2015). Diabetes is reversed in a murine model by marginal mass syngeneic islet transplantation using a subcutaneous cell pouch device. *Transplantation*, 99, 2294–2300.
- Riccardo, C. (2018). Microencapsulation for cell therapy of type 1 diabetes mellitus: The interplay between common beliefs, prejudices and real progress. *Journal of Diabetes Investigation*, 9, 231–233.
- Scharp, D. W., & Marchetti, P. (2014). Encapsulated islets for diabetes therapy: History, current progress, and critical issues requiring solution. Advanced Drug Delivery Reviews, 67-68, 35-73.

- Weidling, J., Sameni, S., Lakey, J. R. T., & Botvinick, E. (2014). Method measuring oxygen tension and transport within subcutaneous devices. *Journal of Biomedical Optics*, 19, 087006.
- Yang, H. K., Ham, D. S., Park, H. S., Rhee, M., You, Y. H., Kim, M. J., ... Yoon, K. H. (2016). Long-term efficacy and biocompatibility of encapsulated islet transplantation with chitosan-coated alginate capsules in mice and canine models of diabetes. *Transplantation*, 100, 334–343.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Cao R, Avgoustiniatos E, Papas K, de Vos P, Lakey JRT. Mathematical predictions of oxygen availability in micro- and macro-encapsulated human and porcine pancreatic islets. *J Biomed Mater Res.* 2019;1–10. https://doi.org/10.1002/jbm.b.34393

/ILEY